Daewoong Pharmaceutical said Wednesday its Nabota botulinum toxin demonstrated statistically meaningful results in Phase 3 trials in China, signaling an imminent entry to the market, the second largest botulinum toxin market in the world.
Following the success of mRNA Covid-19 vaccines like those of Moderna and Pfizer, local companies and the Korean government are rushing investments into the state-of-art vaccine technology.
After emerging victorious in a protracted trade secrets dispute last year, Medytox has received billions of dollars in license fees and royalty fees and bought a stake in the U.S. botulinum toxin maker Evolus, becoming its second largest stakeholder.
Daewoong Pharmaceutical’s Foister tablets received a nod from the government for Phase 3 clinical trials as a preventive drug, the company said Monday.
Daewoong Pharmaceutical will receive government funding to establish production facilities for its Covid-19 treatment candidate. The company will receive a maximum 19 trillion won ($17.2 billion) from the Ministry of Health and Welfare by until 2021.
After a two-year investigation, the U.S. International Trade Commission has made a final determination in favor of Medytox in its high-profile “Botox brawl” with Daewoong Pharmaceutical.
Boryung Pharmaceutical’s production line for cancer drugs that are administered by injection in Yesan, South Chungcheong, was approved for Good Manufacturing Practice (GMP) certification by the Korean Ministry of Food and Drug Safety.
Samsung Biologics signed a contract development organization (CDO) deal with GeneQuantum, a Chinese biotech venture, the Korean company said Monday.
A succession of deaths following flu shots — 28 reported as of Thursday — is fanning fears over the safety of Korean influenza vaccinations, though the government insists a link remains unproven.
Daewoong Pharmaceutical’s Covid-19 drug candidate has won approval to undergo Phase 1 clinical trials in Korea, the company said Monday.